Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

CD33 is expressed on the majority of acute myeloid leukemia (AML) leukemic blasts and is the target for gemtuzumab ozogamicin (GO), a toxin-conjugated anti-CD33 mAb. In the present study, we quantified the CD33 mean fluorescent intensity of leukemic blasts prospectively in 619 de novo pediatric AML...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Pollard, Jessica A., Alonzo, Todd A., Loken, Michael, Gerbing, Robert B., Ho, Phoenix A., Bernstein, Irwin D., Raimondi, Susana C., Hirsch, Betsy, Franklin, Janet, Walter, Roland B., Gamis, Alan, Meshinchi, Soheil
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2012
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3335378/
https://ncbi.nlm.nih.gov/pubmed/22378848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-398370
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi